Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes. (Q34804520)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21436054%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

title

Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21436054%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21436054%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

4

Byungkook Lee

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21436054%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

7

Ira Pastan

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21436054%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

1

Masanori Onda

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21436054%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

6

Robert J Kreitman

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21436054%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

author name string

Richard Beers

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21436054%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Laiman Xiang

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21436054%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

language of work or name

English

0 references

publication date

21 March 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21436054%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

number of pages

6

1 reference

Proceedings of the National Academy of Sciences of the United States of America

inferred from page(s)

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21436054%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

volume

108

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21436054%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

issue

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21436054%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

page(s)

5742-5747

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21436054%20AND%20SRC:MED&resulttype=core&format=json

A recombinant immunotoxin targeting CD22 with low immunogenicity, low nonspecific toxicity, and high antitumor activity in mice.

26 January 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078343

Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078343

Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078343

A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078343

An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078343

Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078343

Immunogenicity of engineered antibodies

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078343

HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078343

Modifying an immunogenic epitope on a therapeutic protein: a step towards an improved system for antibody-directed enzyme prodrug therapy (ADEPT)

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078343

Minimizing the immunogenicity of protein therapeutics

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078343

Recombinant immunotoxins in the treatment of cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078343

Immune responses to therapeutic proteins in humans--clinical significance, assessment and prediction

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078343

Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078343

Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078343

Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078343

Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078343

Identification of epitopes on a mutant form of Pseudomonas exotoxin using serum from humans treated with Pseudomonas exotoxin containing immunotoxins

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078343

Gene splicing by overlap extension: tailor-made genes using the polymerase chain reaction

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078343

Immunotoxin therapy of cancer

8 July 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.1102746108

Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.1102746108

Releasable PEGylation of mesothelin targeted immunotoxin SS1P achieves single dosage complete regression of a human carcinoma in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.1102746108

Elimination of an immunodominant CD4+ T cell epitope in human IFN-beta does not result in an in vivo response directed at the subdominant epitope

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.1102746108

An in vitro human cell-based assay to rank the relative immunogenicity of proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.1102746108

Lowering the isoelectric point of the Fv portion of recombinant immunotoxins leads to decreased nonspecific animal toxicity without affecting antitumor activity

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078343

Recombinant staphylokinase variants with reduced antigenicity due to elimination of B-lymphocyte epitopes

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078343

Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients

26 October 2018

1 reference

12 December 2020

Inhibition of TNF-alpha produced by Kupffer cells protects against the nonspecific liver toxicity of immunotoxin anti-Tac(Fv)-PE38, LMB-2

1 reference

12 December 2020

Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers

1 reference

12 December 2020

Recombinant staphylokinase variants with altered immunoreactivity. I: Construction and characterization

1 reference

12 December 2020

Recombinant staphylokinase variants with altered immunoreactivity. II: Thrombolytic properties and antibody induction

1 reference

12 December 2020

Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias

1 reference

12 December 2020

Identifiers

DOI

10.1073/PNAS.1102746108

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21436054%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21436054%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

PubMed publication ID

21436054

1 reference